Insider Selling: Intuitive Surgical, Inc. (NASDAQ:ISRG) SVP Sells 492 Shares of Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) SVP Mark Brosius sold 492 shares of Intuitive Surgical stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $573.78, for a total value of $282,299.76. Following the sale, the senior vice president now directly owns 4,056 shares of the company’s stock, valued at approximately $2,327,251.68. This represents a 10.82 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Intuitive Surgical Trading Down 1.1 %

NASDAQ:ISRG opened at $566.98 on Tuesday. Intuitive Surgical, Inc. has a 12 month low of $364.17 and a 12 month high of $616.00. The stock has a 50 day moving average of $570.66 and a two-hundred day moving average of $530.08. The firm has a market cap of $201.95 billion, a P/E ratio of 88.45, a price-to-earnings-growth ratio of 5.85 and a beta of 1.39.

Wall Street Analysts Forecast Growth

A number of analysts have commented on ISRG shares. Raymond James lifted their price target on Intuitive Surgical from $560.00 to $688.00 and gave the stock an “outperform” rating in a research report on Friday, January 24th. Stifel Nicolaus boosted their price objective on Intuitive Surgical from $525.00 to $610.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Barclays boosted their price objective on Intuitive Surgical from $610.00 to $674.00 in a report on Monday, January 27th. UBS Group boosted their price objective on Intuitive Surgical from $500.00 to $560.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Finally, Morgan Stanley raised Intuitive Surgical from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $522.00 to $650.00 in a report on Monday, December 2nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $613.10.

Institutional Investors Weigh In On Intuitive Surgical

Several large investors have recently bought and sold shares of the company. Bennett Selby Investments LP increased its stake in Intuitive Surgical by 3.9% during the 4th quarter. Bennett Selby Investments LP now owns 449 shares of the medical equipment provider’s stock worth $234,000 after buying an additional 17 shares in the last quarter. Onefund LLC grew its position in shares of Intuitive Surgical by 1.9% in the fourth quarter. Onefund LLC now owns 947 shares of the medical equipment provider’s stock valued at $494,000 after purchasing an additional 18 shares in the last quarter. AlphaCore Capital LLC grew its position in shares of Intuitive Surgical by 4.2% in the fourth quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider’s stock valued at $235,000 after purchasing an additional 18 shares in the last quarter. LVW Advisors LLC grew its position in shares of Intuitive Surgical by 1.3% in the fourth quarter. LVW Advisors LLC now owns 1,448 shares of the medical equipment provider’s stock valued at $756,000 after purchasing an additional 19 shares in the last quarter. Finally, Wesbanco Bank Inc. grew its position in shares of Intuitive Surgical by 1.6% in the fourth quarter. Wesbanco Bank Inc. now owns 1,216 shares of the medical equipment provider’s stock valued at $635,000 after purchasing an additional 19 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.